NICE guidance recommends considering these medications for specific clinical scenarios where multiple metabolic abnormalities coexist
Rybelsus (Oral): Approved in 2019 (first oral GLP-1 agonist)
When evaluating compounded semaglutide or tirzepatide options, combining your genetic predisposition profile with current disease activity data and IBD-specific biomarkers (fecal calprotectin, CRP) can support a more informed conversation with your provider about which formulation, dose, and monitoring schedule aligns with your health goals
Additionally, tirzepatide did not receive traditional FDA approval for weight loss, while semaglutide went through the normal FDA approval process
Deep Hydration: Infused with 8 Hyaluronic Acid and Panthenol types to lock in moisture and nourish the skin
This helps healthcare professionals prescribe the correct formulation and reduces medication errors